Scientific article

The Future of Cancer Immunotherapy

ContributorsMach, Nicolas
Published inPraxis, vol. 112, no. 3, p. 156-159
Publication date2023

This article describes three emerging, novel cancer immunotherapies: BITE, TIL and cancer vaccines are therapies that recognize specific targets on cancer cells and trigger a specific immune response. So far, not all tumor types can benefit from these approaches the best results have been observed in hematological malignancies, melanoma, and lung cancer. These novel biological products are currently being tested in several cancer centers in Switzerland, and physicians must be familiar with these procedures, as some of their patients might be treated with such therapies in the near future.

  • Immunotherapy
  • Immunothérapie
  • Immuntherapie
  • Immunüberwachung
  • Krebsimpfstoffe
  • Tumor-infiltrierende Lymphozyten
  • Anticorps bi-spécifiques engageant les cellules T
  • Bi-specific antibody T-cell engager
  • Bi-spezifischer Antikörper T-Zell-Engager
  • Cancer vaccines
  • Immunosurveillance
  • Lymphocytes infiltrant les tumeurs
  • Tumor-infiltrating lymphocytes
  • Vaccins contre le cancer
  • Humans
  • Biological Products
  • Hematologic Neoplasms
  • Lung Neoplasms / therapy
  • Physicians
Citation (ISO format)
MACH, Nicolas. The Future of Cancer Immunotherapy. In: Praxis, 2023, vol. 112, n° 3, p. 156–159. doi: 10.1024/1661-8157/a003975
Main files (1)
Article (Published version)
ISSN of the journal1661-8157

Technical informations

Creation12/06/2023 1:20:18 PM
First validation03/20/2024 1:55:28 PM
Update time03/20/2024 1:55:28 PM
Status update03/20/2024 1:55:28 PM
Last indexation03/20/2024 1:55:49 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack